(Q28373205)

English

GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist

scientific article

GlycineB antagonists and partial agonists in rodent models of Parkinson’s disease—comparison with uncompetitive N-methyl-d-aspartate receptor antagonist

In more languages

Statements

scholarly article

0 references

GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist (English)

0 references

Parkinson's disease

1 reference

based on heuristic

inferred from title

Wojciech Danysz

3

object named as

W Danysz

0 references

author name string

M Karcz-Kubicha

1

0 references

B Lorenz

2

0 references

language of work or name

0 references

publication date

January 1999

0 references

Neuropharmacology

0 references

38

0 references

1

0 references

109-19

0 references

Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Current drug therapy for Parkinson's disease. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Glutamate antagonists have different effects on spontaneous locomotor activity in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?--case of amantadine and memantine

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

The effect of adding amantadine to optimum L-dopa dosage in Parkinson's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Impairments of movement initiation and execution induced by a blockade of dopamine D1 or D2 receptors are reversed by a blockade of N-methyl-D-aspartate receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Anxiolytic activity of glycine-B antagonists and partial agonists--no relation to intrinsic activity in the patch clamp.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

D-Cycloserine: Agonist turned antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Dopamine/glutamate interaction as studied by combining turning behaviour and c-Fos expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Common and uncommon behavioural effects of antagonists for different modulatory sites in the NMDA receptor/channel complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

The role of excitatory amino acids in experimental models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Behavioural pharmacology of glutamate receptors in the basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Anticataleptic potencies of glutamate-antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Amantadine in the Treatment of Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Paradoxical anticonvulsant activity of the gamma-aminobutyrate antagonist bicuculline methiodide in the rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900165-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0028-3908(98)00165-8

0 references

release_x7a23wv3cnfhzamo4ixewxqzmu

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28373205&oldid=2079226153"